OncoMatch/Clinical Trials/NCT06414954
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Is NCT06414954 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies NMD670 for myasthenia gravis.
Treatment: NMD670 — This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CHRNA1 antibody positive
Documented positive AChR or MuSK antibody test.
Required: MUSK antibody positive
Documented positive AChR or MuSK antibody test.
Performance status
MGFA 2–4
Prior therapy
Cannot have received: investigational medical product
Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Profound Research LLC · Carlsbad, California
- University of California Irvine Medical Center · Irvine, California
- University of Colorado Neuromuscular Division · Aurora, Colorado
- SFM Clinical Research, LLC · Boca Raton, Florida
- Neuromuscular Research Division | University of South Florida · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify